DDInter166 DDInter875
A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Basiliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Basiliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Basiliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Basiliximab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Basiliximab {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Basiliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Basiliximab may lead to a major life threatening interaction when taken with Upadacitinib
Basiliximab may lead to a major life threatening interaction when taken with Infliximab